A Phase 3 interventional study of LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 23 sites in 2 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 14th largest by enrollment, is the only one that started in 2020, is one of 10 in phase 3, and was the 20th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2020.
This study's enrollment of 52 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 75th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2020, is one of 62 in phase 3, and was the 92nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to \<24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.
Key Inclusion Criteria:
Participants From Study VX16-809-122 Part B (Study 122)
Participants Not From Study 122
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing 7 to less than (\<) 9 kilograms (kg) received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h in the treatment period of 96 weeks. Participants weighing greater than or equal to (\>=)14 kg received LUM 150 mg/IVA 188 mg FDC q12h in the treatment period of 96 weeks.
Drug: LUM/IVA
Drug pages: Lumacaftor · Ivacaftor
LUM/IVA granules for oral administration
Also known as: lumacaftor/ivacaftor, VX-809/VX-770
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 120
Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 96
The study was conducted in participants with cystic fibrosis (CF) aged 12 months through less than (\<) 24 months of age at treatment initiation who were homozygous for F508del and participants who completed the 24-week treatment period along with the safety follow-up in study VX16-809-122 (NCT03601637) Part B.
| Milestone | LUM/IVA |
|---|---|
| Started | 52 |
| Rollover participants | 39 |
| Lumacaftor (lum)/ ivacaftor (iva)-naïve participants | 13 |
| Completed | 38 |
| Not completed | 14 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 4 |
| Withdrew: Commercial drug is available for participants | 7 |
| Participants | LUM/IVA |
|---|---|
| Participants with TEAEs | 52 |
| Participants with SAEs | 12 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | LUM/IVA |
|---|---|
| Absolute Change in Sweat Chloride (SwCl) | -21.0 ± 14.9 |
Collected over Day 1 to Week 120. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM/IVA | 0/52 (0%) | 12/52 (23.1%) | 50/52 (96.2%) |
| Event | LUM/IVA |
|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 6/52 |
| ConstipationGastrointestinal disorders | 2/52 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 1/52 |
| Anaphylactic reactionImmune system disorders | 1/52 |
| COVID-19Infections and infestations | 1/52 |
| Cellulitis orbitalInfections and infestations | 1/52 |
| Lower respiratory tract infection viralInfections and infestations | 1/52 |
| Oral herpesInfections and infestations | 1/52 |
| Parainfluenzae virus infectionInfections and infestations | 1/52 |
| SinusitisInfections and infestations | 1/52 |
| Event | LUM/IVA |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 25/52 |
| Upper respiratory tract infectionInfections and infestations | 16/52 |
| PyrexiaGeneral disorders | 15/52 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 15/52 |
| ConstipationGastrointestinal disorders | 14/52 |
| VomitingGastrointestinal disorders | 14/52 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 14/52 |
| COVID-19Infections and infestations | 12/52 |
| Ear infectionInfections and infestations | 12/52 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 9/52 |
Baseline value was defined as the most recent non-missing measurement (scheduled or unscheduled) collected on or before the first dose of LUM/IVA in this study.
| Age, Continuous(months) | LUM/IVA |
|---|---|
| Mean | 18.8 ± 3.32 |
| Sex: Female, Male(Participants) | LUM/IVA |
|---|---|
| Female | 24 |
| Male | 28 |
| Race/Ethnicity, Customized(Participants) | LUM/IVA |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 43 |
| Not collected per local regulations | 8 |
| Race/Ethnicity, Customized(Participants) | LUM/IVA |
|---|---|
| White | 40 |
| Black or African American | 0 |
| Asian | 0 |
| American Indian or Alaska Native | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Not collected per local regulations | 8 |
| Other | 1 |
| More than one race | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.
Ran from Feb 2020 to primary completion in Aug 2023, 41 months.
Results were first posted in Sep 2024, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 41 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →